Want to see IRLA full AI Analyst Report?
Total Valuation
IRulya Therapeutics has a market cap or net worth of $32.95M. The enterprise value is $139.39M.
Market Cap$32.95M
Enterprise Value$139.39M
Share Statistics
IRulya Therapeutics has 1,017,063 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,017,063
Owned by Insiders50.74%
Owned by Institutions0.39%
Financial Efficiency
IRulya Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count38
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of IRulya Therapeutics is ―. IRulya Therapeutics’s PEG ratio is -0.07.
PE Ratio―
PS Ratio0.00
PB Ratio-4.70
Price to FCF-4.02
Price to Operating Cash Flow―
PEG Ratio-0.07
Income Statement
In the last 12 months, IRulya Therapeutics had revenue of ― and earned ― in profits. Earnings per share was ―.
Revenue―
Gross Profit―
Operating Income―
Pretax Income―
Net Income―
EBITDA―
Earnings Per Share (EPS)―
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
IRulya Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.76
52-Week Price Change-91.73%
50-Day Moving Average30.41
200-Day Moving Average98.79
Relative Strength Index (RSI)56.90
Average Volume (3m)25.82K
Important Dates
IRulya Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
IRulya Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, IRulya Therapeutics has paid ― in taxes.
Income Tax―
Effective Tax Rate―
Enterprise Valuation
IRulya Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
IRulya Therapeutics has ― in cash and marketable securities with $0.00 in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt$0.00
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for IRulya Therapeutics is $75.63, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$75.63
Price Target Upside144.50% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast43.02%